JP2012504401A5 - - Google Patents

Info

Publication number

JP2012504401A5

JP2012504401A5 JP2011529559A JP2011529559A JP2012504401A5 JP 2012504401 A5 JP2012504401 A5 JP 2012504401A5 JP 2011529559 A JP2011529559 A JP 2011529559A JP 2011529559 A JP2011529559 A JP 2011529559A JP 2012504401 A5 JP2012504401 A5 JP 2012504401A5

Authority

JP

Japan

Prior art keywords

seq

sequence

antibody

cdr

functional fragment

Prior art date

2009-10-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims description 26
• 150000001875 compounds Chemical class 0.000 claims description 17
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 150000007523 nucleic acids Chemical class 0.000 claims 10
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims 8
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 7
• 210000004027 cell Anatomy 0.000 claims 7
• 108020004707 nucleic acids Proteins 0.000 claims 7
• 102000039446 nucleic acids Human genes 0.000 claims 7
• 239000008194 pharmaceutical composition Substances 0.000 claims 7
• 238000000225 bioluminescence resonance energy transfer Methods 0.000 claims 5
• 230000002401 inhibitory effect Effects 0.000 claims 5
• 238000000034 method Methods 0.000 claims 5
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
• 206010028980 Neoplasm Diseases 0.000 claims 3
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
• 230000004913 activation Effects 0.000 claims 3
• 201000011510 cancer Diseases 0.000 claims 3
• 210000004408 hybridoma Anatomy 0.000 claims 3
• 238000004458 analytical method Methods 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 230000001939 inductive effect Effects 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 2
• 239000002773 nucleotide Substances 0.000 claims 2
• 125000003729 nucleotide group Chemical group 0.000 claims 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
• 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
• 206010009944 Colon cancer Diseases 0.000 claims 1
• 101710112752 Cytotoxin Proteins 0.000 claims 1
• 108020004414 DNA Proteins 0.000 claims 1
• 206010014733 Endometrial cancer Diseases 0.000 claims 1
• 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
• 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
• 208000034578 Multiple myelomas Diseases 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
• 239000004480 active ingredient Substances 0.000 claims 1
• 230000000259 anti-tumor effect Effects 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 208000029742 colonic neoplasm Diseases 0.000 claims 1
• 230000000295 complement effect Effects 0.000 claims 1
• 230000021615 conjugation Effects 0.000 claims 1
• 210000004748 cultured cell Anatomy 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 239000000824 cytostatic agent Substances 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 239000002254 cytotoxic agent Substances 0.000 claims 1
• 231100000599 cytotoxic agent Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 239000002619 cytotoxin Substances 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 239000001963 growth medium Substances 0.000 claims 1
• 239000000833 heterodimer Substances 0.000 claims 1
• 239000000710 homodimer Substances 0.000 claims 1
• 201000005202 lung cancer Diseases 0.000 claims 1
• 208000020816 lung neoplasm Diseases 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 201000008968 osteosarcoma Diseases 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 238000012216 screening Methods 0.000 claims 1
• 230000009261 transgenic effect Effects 0.000 claims 1